-
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
NCT05077137 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06413680 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
NCT07317505 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Wilson
-
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406 ·
Phase: Phase 2, Phase 3 ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Asheville, Charlotte, Durham, Wilmington
-
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Clemmons, Clinton, Goldsboro, Jacksonville
-
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
NCT07749586 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT06940739 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Albemarle, Asheboro, Burlington, Charlotte
-
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Clinton, Goldsboro, Jacksonville
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Asheville, Cary, Clinton, Clyde
-
DESTINY-PANTUMOUR04
NCT07124000 ·
Phase: Not specified ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· North Carolina: Durham, Wilson
-
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
DermaSensor Postmarket Surveillance Study
NCT06666790 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years and older ·
Sex: All (male and female)
· North Carolina: Morehead City
-
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
NCT05839912 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
IL-17 Blockade to Decrease irAEs (REPLAY)
NCT07237594 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Integrated Cancer Repository for Cancer Research
NCT02012699 ·
Phase: Not specified ·
Ages: 19 Years to 110 Years ·
Sex: All (male and female)
· North Carolina: Fayetteville
-
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT05076760 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Durham, Greenville, Hillsborough
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Project: Every Child for Younger Patients With Cancer
NCT02402244 ·
Phase: Not specified ·
Ages: Up to 25 Years ·
Sex: All (male and female)
· North Carolina: Asheville, Chapel Hill, Charlotte, Durham
-
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Winston-Salem
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT03454035 ·
Phase: Phase 1 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Durham
-
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT04389281 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham